Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally

Related Content

FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?

Jan 04 2009

CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class

Jan 12 2009

FDA Clears Forest’s Savella, The First Fibromyalgia-Only Drug

Jan 15 2009

FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins

Sep 29 2008

FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs

Mar 17 2008

FDA Communication On Missed Deadlines Can Help Avoid Drug Review Limbo

Dec 22 2008

FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count

Jan 14 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window